IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
基本信息
- 批准号:8675925
- 负责人:
- 金额:$ 39.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-15 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:AllograftingAntigensAutoimmune ResponsesAutoimmunityBone MarrowBronchiolitisBronchiolitis ObliteransCellsChimera organismChronicCollagenComplicationCystic FibrosisDataDevelopmentEpithelialFibrosisGoalsGraft RejectionHumanImmuneImmunobiologyImmunologistImmunologyImmunosuppressive AgentsInflammatoryInjuryInterleukin-10Interleukin-17Interleukin-6KnowledgeLesionLungLung TransplantationLung diseasesMediatingMissionModelingMorbidity - disease rateMusObstructionOrganOutcomePathologicPatientsPre-Clinical ModelPrincipal InvestigatorProbabilityProcessProductionPublic HealthPulmonary EmphysemaPulmonary FibrosisResearchResearch PersonnelRodentRodent ModelSerumSignal TransductionSolidSourceSurvival RateSyndromeT-Cell Immunologic SpecificityT-LymphocyteTestingTherapeutic InterventionTransplant RecipientsTransplantationWorkcell typeclinically relevantcytokineeffective therapygraft failureimprovedinjured airwayinnovationlung allograftmortalitymouse modelnovelpreventtherapy developmenttool
项目摘要
DESCRIPTION (provided by applicant): The 5 year survival rate of 50% for lung transplant patients is much lower compared to other solid organs due to the late complication of bronchiolitis obliterans syndrome for which there is no effective treatment. Bronchiolitis obliterans syndrome (BOS) is characterized by obliterative bronchiolitis (OB) of the airways and is immune-mediated chronic rejection of the lung. The long-term goal is to develop novel therapies to treat patients with OB/BOS. Cellular and humoral autoimmune responses can induce OB in rodent models and are associated with BOS in humans. The T cells found to be mediating autoimmunity were CD4+ IL-17 producing T cells. These studies suggest autoreactive Th17 cells promote airway injury and OB. However, the mechanisms by which IL-17 mediates airway obliteration are not known. The objective of this application is to determine the mechanisms by which IL-17 promotes lung allograft obliterative bronchiolitis. Research has been significantly hampered by the lack of a clinically relevant murine model of OB. We have now developed a novel mouse model of orthotopic lung transplantation, which unlike other models of lung transplant in rodents, develops reproducible obliteration of the airways identical to the lesion found in humans. The central hypothesis of this application is that IL-17 produced by allograft reactive T cells promotes airway fibrosis. Our hypothesis has been formulated by our own preliminary data that IL-17 blockade prevents airway fibrosis and obliteration in allografts in our model. The specific aims are: 1) Determine the extent to which T cells and IL- 17A or IL-17F are required for the development of OB; 2) Determine mechanisms by which IL-17 blockade prevents development of OB. The rationale for the proposed research is that elucidating the mechanisms by which IL-17 promotes fibrosis and by which blockade of IL-17 prevents OB will identify novel targets for therapy for OB. The proposed research is significant because it is expected to expand understanding of how OB develops and can be prevented. In our opinion, the proposed research is innovative because we have developed a reproducible pre-clinical model of OB that has a high probability of identifying novel targets for therapeutic intervention.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rebecca A. Shilling其他文献
Rebecca A. Shilling的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rebecca A. Shilling', 18)}}的其他基金
IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
- 批准号:
8494688 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别:
IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
- 批准号:
8302213 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别:
IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
- 批准号:
8161842 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别:
IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
- 批准号:
8847365 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别:
相似国自然基金
基于表达MHC-肽嵌合抗原受体T细胞治疗自身免疫疾病的策略和机制研究
- 批准号:81901643
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
胰岛β细胞ERS诱导的MHC-Ⅰ类分子相关新生抗原肽鉴定及其在NOD小鼠胰岛早期启动CD8+T细胞活化中的作用
- 批准号:81871301
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
自体抗原Col I通过IL-17介导肝移植术后慢性排斥反应的机制研究
- 批准号:81571564
- 批准年份:2015
- 资助金额:50.0 万元
- 项目类别:面上项目
免疫反应在神经系统自身免疫疾病及其神经干细胞治疗中的作用机制
- 批准号:31570995
- 批准年份:2015
- 资助金额:71.0 万元
- 项目类别:面上项目
自身抗原KINECTIN在白塞病中启动自身免疫炎症反应的机制研究
- 批准号:30972744
- 批准年份:2009
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Lung Allograft Stem Cell Regeneration and Immune Destruction
同种异体肺干细胞再生和免疫破坏
- 批准号:
10370655 - 财政年份:2022
- 资助金额:
$ 39.08万 - 项目类别:
Lung Allograft Stem Cell Regeneration and Immune Destruction
同种异体肺干细胞再生和免疫破坏
- 批准号:
10545033 - 财政年份:2022
- 资助金额:
$ 39.08万 - 项目类别:
Transplant Associated Autoimmunity Contributes to Allograft Damage
移植相关的自身免疫导致同种异体移植物损伤
- 批准号:
8030720 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别:
IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
- 批准号:
8494688 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别:
IL-17 and Lung Transplant Obliterative Bronchiolitis
IL-17 与肺移植闭塞性细支气管炎
- 批准号:
8302213 - 财政年份:2011
- 资助金额:
$ 39.08万 - 项目类别: